Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Recommendation of “Buy” from Brokerages

Protara Therapeutics, Inc. (NASDAQ:TARA) has earned an average recommendation of “Buy” from the six research firms that are covering the company, Marketbeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokers that have issued a report on the stock in the last year is $20.40.

Several research analysts have weighed in on the company. HC Wainwright restated a “buy” rating and issued a $23.00 price target on shares of Protara Therapeutics in a research note on Thursday, March 6th. Scotiabank started coverage on shares of Protara Therapeutics in a research report on Wednesday, April 16th. They set a “sector outperform” rating and a $12.00 target price for the company. Cantor Fitzgerald began coverage on shares of Protara Therapeutics in a research note on Friday, March 14th. They set an “overweight” rating for the company. Finally, Lifesci Capital started coverage on shares of Protara Therapeutics in a research note on Tuesday, March 11th. They issued an “outperform” rating and a $22.00 price target on the stock.

Insider Buying and Selling

In other Protara Therapeutics news, insider Jacqueline Zummo sold 21,224 shares of the business’s stock in a transaction that occurred on Wednesday, March 26th. The stock was sold at an average price of $4.53, for a total transaction of $96,144.72. Following the sale, the insider now directly owns 98,861 shares of the company’s stock, valued at $447,840.33. The trade was a 17.67 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 12.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Protara Therapeutics

Several institutional investors have recently modified their holdings of the stock. XTX Topco Ltd purchased a new stake in Protara Therapeutics during the 3rd quarter valued at $60,000. Geode Capital Management LLC increased its position in Protara Therapeutics by 21.0% during the third quarter. Geode Capital Management LLC now owns 170,040 shares of the company’s stock valued at $311,000 after acquiring an additional 29,514 shares during the last quarter. Oppenheimer & Co. Inc. increased its position in Protara Therapeutics by 12.4% during the fourth quarter. Oppenheimer & Co. Inc. now owns 201,426 shares of the company’s stock valued at $1,064,000 after acquiring an additional 22,301 shares during the last quarter. Bailard Inc. purchased a new stake in shares of Protara Therapeutics in the fourth quarter valued at $157,000. Finally, Commonwealth Equity Services LLC lifted its holdings in shares of Protara Therapeutics by 90.4% in the 4th quarter. Commonwealth Equity Services LLC now owns 37,000 shares of the company’s stock worth $195,000 after acquiring an additional 17,572 shares during the last quarter. 38.13% of the stock is owned by institutional investors.

Protara Therapeutics Stock Performance

TARA opened at $3.90 on Wednesday. The stock has a market cap of $143.39 million, a price-to-earnings ratio of -1.38 and a beta of 1.60. The firm’s fifty day moving average is $4.04 and its 200 day moving average is $3.92. Protara Therapeutics has a fifty-two week low of $1.60 and a fifty-two week high of $10.48.

Protara Therapeutics (NASDAQ:TARA) last announced its quarterly earnings data on Wednesday, March 12th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.09. On average, equities research analysts predict that Protara Therapeutics will post -3.32 earnings per share for the current year.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.